AIM ImmunoTech Inc. — Director's Dealing 2017

Jul 17, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2017-07-15

Reporting Person: Springate Wayne S. (Sr. VP of Operations)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-07-15	Options to buy Common Stock	$0.48	A	5438	Acquired	2027-07-15	Common Stock (5438)	Direct

Footnotes

F1: This option is being issued in exchange for a voluntary 20% deduction in salary.